Rupali Mukherjee
₹4,000 weight-loss shots are coming to India. The real shift is what comes with them
As semaglutide’s patent expires on March 20 the entry of generics is set to nearly halve treatment costs, opening up injectable anti-obesity treatment. But pharma firms, trying to stand out in a crowded room, are looking beyond simple price cuts, eyeing an entire weight-loss ecosystem. This could include diet plans, counselling and clinic partnerships
Why 'miracle' weight loss drugs are about to get 50% cheaper in India
With semaglutide’s patent expiring, generics are set to enter from soon, setting off competition in a fast-growing segment of obesity and diabetes care
Novartis, Pfizer, Sanofi: How India's pharma GCCs transformed from back office to innovation powerhouse
They may have started out by processing routine tasks for global majors, but Indian pharma GCCs have now become a magnet for talent and investment as tech advances throw up new opportunities
Why weight-loss drug prices are set to fall steeply starting next year
A key weight-loss drug goes off-patent next year. A US study estimates its production cost to be less than 2% of its selling price. It means cheaper generic options for Indians
Brands discover power of payer in pilgrim rush
As UP basks in Maha Kumbh bounty, religious tourism in India is transforming the pilgrimage economy, throwing up lucrative opportunities for businesses
Why are pharma MNCs reducing India footprint?
Many have sold popular generic brands and even factories to big domestic firms, but experts say they’re doing this to focus on core strengths, high-value products
- Rupali Mukherjee
- TIMESOFINDIA.COM
Why Starbucks costs more in India than US
What’s considered a ‘value’ brand abroad is often positioned as a ‘premium’ one in India. What’s the logic behind the different pricing strategies adopted by MNC brands?
Why world needs patent-free Covid meds now
Waiving IP rights on medicines and diagnostics will help fight the pandemic in poor countries; but World Trade Organization members' have again deferred the decision
- Rupali Mukherjee
- TIMESOFINDIA.COM
Thanks to non-tech companies, it's best time to be techie in India
FMCG, pharma, manufacturing, construction – across sectors there is need for IT professionals as digitisation affects every industry
When big pharma must give up its monopoly over life-saving drugs
Pandemic showed how crucial cheap generic medicines are. But can Big Pharma be made to agree?
How Dolo 650 rode on social media to become a superbrand
It’s quite a journey from being a medicine prescribed to reduce fever to becoming a viral meme. While it may not have been what the makers of Dolo 650 had planned, this kind of virality has definitely helped sales during the pandemic
Global inequality: New drugs go the way of vaccines
WTO mustn’t delay the waiver of intellectual property rights for Covid-19 therapies any more
Why Covaxin hasn’t delivered what it promised
India’s home-grown Covid vaccine, Covaxin has come in for a fair share of criticism with low supplies and failure to receive WHO approval. Here’s a look at why the Bharat Biotech vaccine has failed to deliver as promised
- Rupali Mukherjee
- TIMESOFINDIA.COM
Indian men are now 'coming out of the closet' with 'brotox'
'Brotox' — the latest fancy of the Indian male — is slowly but surely gaining ground, with more and more men saying appearance is very important